Challenges with Integrating Real-World Evidence for ARPI Use in mCSPC

In ‘Challenges with Integrating Real-World Evidence for ARPI Use in mCSPC,’ our panel explores how real-world evidence informs treatment decisions for patients receiving androgen receptor pathway inhibitors (ARPIs) in metastatic castration-sensitive prostate cancer (mCSPC). The expert faculty discuss the opportunities and limitations of comparative analyses, highlighting the importance of understanding potential biases and patient-level factors when applying real-world findings to clinical practice.

The panel examines how treatment characteristics—including administration requirements, toxicity profiles, and adherence considerations—can influence both patient outcomes and the interpretation of comparative data. They emphasize that while real-world evidence can provide valuable insights beyond those available from randomized clinical trials, careful evaluation of study design and patient populations remains essential.

Throughout the discussion, the panelists underscore the importance of patient education, individualized treatment selection, and practical considerations that may affect long-term treatment success. By balancing emerging evidence with the realities of clinical practice, clinicians can make more informed decisions and optimize care for patients with mCSPC.

Our next episode, ‘Managing ARPI Toxicities and Treatment Goals in mCSPC,’ explores how clinicians incorporate toxicity profiles, comorbidities, bone health, and patient preferences into treatment selection and management. The panelists also discuss how clinical trial endpoints and individual treatment goals influence shared decision-making in patients with mCSPC.